Literature DB >> 6626452

Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells.

F Colotta, A Rambaldi, N Colombo, L Tabacchi, M Introna, A Mantovani.   

Abstract

The streptococcal preparation OK432 was studied for its effects on natural killer (NK) activity of peripheral blood lymphocytes (PBL) from normal donors and from ovarian cancer patients, and of tumour-associated lymphocytes (TAL) from peritoneal effusions. OK432 augmented NK activity against the susceptible K562 line and induced killing of the relatively resistant Raji line. Freshly isolated ovarian carcinoma cells were relatively resistant to killing by unstimulated PBL and TAL. OK432 induced significant, though low, levels of cytotoxicity against 51Cr-labelled ovarian carcinoma cells. Augmentation of killing of fresh tumour cells by OK432 was best observed in a 20 h assay and both autologous and allogeneic targets were lysed. PBL were separated on discontinuous Percoll gradients. Unstimulated and OK432-boosted activity were enriched in the lower density fractions where large granular lymphocytes (LGL) and activity against K562 were found. Thus, OK432 augments NK activity of PBL and TAL in human ovarian carcinomas and induces low, but significant, levels of killing of fresh tumour cells. Effector cells involved in killing of fresh ovarian tumours copurify with LGL on discontinuous gradients of Percoll.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6626452      PMCID: PMC2011501          DOI: 10.1038/bjc.1983.224

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

Review 1.  Morphological and functional characterization of isolated effector cells responsible for human natural killer activity to fetal fibroblasts and to cultured cell line targets.

Authors:  E Saksela; T Timonen; A Ranki; P Häyry
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

Review 2.  Natural cell-mediated immunity.

Authors:  R B Herberman; H T Holden
Journal:  Adv Cancer Res       Date:  1978       Impact factor: 6.242

3.  Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon.

Authors:  J M Zarling; L Eskra; E C Borden; J Horoszewicz; W A Carter
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

4.  Human natural cell-mediated cytotoxicity against fetal fibroblasts. III. Morphological and functional characterization of the effector cells.

Authors:  T Timonen; A Ranki; E Saksela; P Häyry
Journal:  Cell Immunol       Date:  1979-11       Impact factor: 4.868

5.  Fractionation, morphological and functional characterization of effector cells responsible for human natural killer activity against cell-line targets.

Authors:  T Timonen; E Saksela; A Ranki; P Häyry
Journal:  Cell Immunol       Date:  1979-11       Impact factor: 4.868

6.  Lymphocyte cytotoxicity against autologous tumour biopsy cells in humans.

Authors:  B M Vose; F Vanky; E Klein
Journal:  Int J Cancer       Date:  1977-10-15       Impact factor: 7.396

7.  Human tumour--lymphocyte interaction in vitro. V. Comparison of the reactivity of tumour-infiltrating, blood and lymph-node lymphocytes with autologous tumour cells.

Authors:  B M Vose; F Vánky; E Klein
Journal:  Int J Cancer       Date:  1977-12-15       Impact factor: 7.396

Review 8.  Do natural killer cells engage in regulated reactions against self to ensure homeostasis?

Authors:  G Cudkowicz; P S Hochman
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

9.  Restricted autologous lymphocytotoxicity in lung neoplasia.

Authors:  B M Vose; F Vánky; M Fopp; E Klein
Journal:  Br J Cancer       Date:  1978-09       Impact factor: 7.640

10.  Immunoreactivity by intrinsic lymphoid cells in colorectal carcinoma.

Authors:  J A Werkmeister; E Pihl; A P Nind; G R Flannery; R C Nairn
Journal:  Br J Cancer       Date:  1979-12       Impact factor: 7.640

View more
  7 in total

1.  Mechanism of immunotherapeutic activity of OK-432 in the treatment of peritoneal carcinomatosis.

Authors:  H Fukui; C W Reynolds; B Lenz; M Schneider; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Limb-salvage procedures for osteosarcoma. An alternative to amputation.

Authors:  A C Wong; Y Akahoshi; S Takeuchi
Journal:  Int Orthop       Date:  1986       Impact factor: 3.075

3.  Inhibition of in vitro LAK generation by OK-432.

Authors:  M Yagita; E A Grimm
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Anti-tumor effect of intravesical instillation of OK432 against rat bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.

Authors:  H Tsujihashi; H Matsuda; S Uejima; T Akiyama; T Kurita
Journal:  Urol Res       Date:  1990

5.  Effects of the oral or intratumoral administration of OK432 on the immuno-reactivities of regional lymph nodes in gastric cancer patients.

Authors:  E Yanagawa; T Toge; Y Yamaguchi; H Kuninobu; K Kuroi; Y Kegoya; N Baba; T Takayama; Y Sato
Journal:  Jpn J Surg       Date:  1991-05

6.  Intrapleural administration of OK432 in cancer patients: augmentation of autologous tumor killing activity of tumor-associated large granular lymphocytes.

Authors:  A Uchida; M Micksche; T Hoshino
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  Antitumor effect of the streptococcal preparation OK-432 in a murine model of ovarian cancer.

Authors:  A Lichtenstein
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.